UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	45-5401931
(State of incorporation or organization)	(I.R.S. Employer Identification No.)
880 Third Avenue, 12th Floor	
New York, NY	10022
(Address of principal executive offices)	(Zip Code)
Securities to be registered pursuant to Section 12(b) of the Act:	
Title of each class	Name of each exchange on which
to be so registered	each class is to be registered
Common stock, \$0.001 par value per share	The NASDAQ Stock Market LLC
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A(d), check the following box. Securities Act registration statement file number to which this form relates: Form S-1, File No.333-233228	
Securities to be registered pursuant to Section 12(g) of the Act:	
None	
(Title of Class)	

Item 1. Description of Registrant's Securities to be Registered.

Relmada Therapeutics, Inc. (the "Registrant") hereby incorporates by reference the description of its common stock, par value \$0.001 per share, to be registered hereunder contained under the heading "Description of Securities" in the Registrant's Registration Statement on Form S-1 (File No. 333-233228), as filed with the Securities and Exchange Commission (the "Commission") on August 12, 2019, as amended from time to time (the "Registration Statement"), and any prospectus that constitutes part of the Registration Statement to be filed separately by the Company with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which information shall also be deemed to be incorporated herein by reference

Item 2. Exhibits.

In accordance with the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

RELMADA THERAPEUTICS, INC.

Date: October 8, 2019 By: /s/ Sergio Travers

By: /s/ Sergio Traversa
Sergio Traversa
Chief Executive Officer